Developing novel immunogens for a safe and effective Alzheimer's disease vaccine

This publication has 55 references indexed in Scilit:

• Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
  The Lancet, 2008
• Shutting Down Alzheimer's
  Scientific American, 2006
• Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies
  Annals of Neurology, 2005
• Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β
  Journal of Neuroscience, 2005
• Differences in the immune response to long term A? vaccination in C57BL/6 and B6D2F1 mice
  Vaccine, 2004
• Alzheimer’s Aβ vaccination of rhesus monkeys (Macaca mulatta)
  Mechanisms of Ageing and Development, 2004
• Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
  Science, 2002
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
  Science, 2002
• Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
  Nature Neuroscience, 2002
• Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets
  Neurochemistry International, 2002